邮箱:xuruishen@fudan.edu.cn
研究方向:脑疾病相关离子稳态的分子机制
经历简介:
教育经历
2016.9-2022.6 中国科学院上海药物研究所,药理学,理学博士
2012.9-2016.6 兰州大学,生命科学与技术基地班,理学学士
代表性论文
(1) Shen X, Sun P, Zhang H, Yang H. Mitochondrial quality control in the brain: The physiological and pathological roles, Frontiers in Neuroscience, 2022, 16.
(2) Xia B#, Shen X#, He Y#, Pan X#, Liu FL#, Wang Y, Yang F, Fang S, George F.G, Duan Z, Zuo X, Xie Z, Jiang X, Xu L, Chi H, Li SQ, Meng Q, Zhou H, Zhou Y, Cheng X, Xin X, Jin L, Zhang HL, Yu D, Li MH, Feng X, Chen J, Jiang H, Xiao G, Zheng YT, Zhang L, Shen J, Li J, Gao Z. SARS-CoV-2 envelope protein causes acute respiratory distress syndrome (ARDS)-like pathological damages and constitutes an antiviral target, Cell Research, 2021, 31(8): 847-860.
(3) Xia B#, Pan X#, Luo RH#, Shen X#, Li S, Wang Y, Zuo X, Wu Y, Guo Y, Xiao G, Li Q, Long X, He X, Zheng HY, Lu Y, Pang W, Zheng YT, Li J, Zhang LK, Gao Z. Extracellular vesicles mediate antibody-resistant transmission of SARS-CoV-2, Cell Discovery, 2023, 9(1).
(4) Xia B#, Qie J#, Shen X, Wang S, Gao Z. Enhanced channel activity by PI(4,5)P2 ignites MLKL-related pathogenic processes, Cell Discovery, 2022, 8(1).
(5) Wang Y#, Fang S#, George F.G, Cheng X, Zhang L, Shen X, Li S, Xu J, Shang W, Gao Z, Xia B. Discovery of SARS-CoV-2-E channel inhibitors as antiviral candidates, Acta pharmacologica Sinica, 2022, 43(4): 781-787.
学术奖励
上海市“超级博士后”(2023)
上海市优秀毕业生(2022)
中国科学院上海药物研究所研究生学术年会大会报告二等奖(2022)
中国科学院上海药物研究所优秀共青团干部(2019)
中国科学院大学三好学生(2018-2019)
兰州大学优秀毕业生(2016)